Promis Neurosciences’ (PMN) “Buy” Rating Reiterated at HC Wainwright

Posted by Brenda Bartman on Jun 24th, 2026

Promis Neurosciences (NASDAQ:PMN – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $18.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 68.38% from the stock’s previous close.

Several other research firms also recently issued reports on PMN. Wall Street Zen raised Promis Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Saturday. Zacks Research upgraded Promis Neurosciences to a “hold” rating in a research note on Tuesday, June 9th. Weiss Ratings downgraded Promis Neurosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Finally, Brookline Capital Markets raised Promis Neurosciences to a “strong-buy” rating in a report on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $26.50.

View Our Latest Research Report on Promis Neurosciences

Promis Neurosciences Trading Up 0.1%

Shares of Promis Neurosciences stock opened at $10.69 on Wednesday. Promis Neurosciences has a 12-month low of $6.27 and a 12-month high of $39.75. The firm has a market capitalization of $95.89 million, a price-to-earnings ratio of -0.74 and a beta of -0.19. The firm’s 50 day simple moving average is $10.69 and its two-hundred day simple moving average is $12.21.

Promis Neurosciences (NASDAQ:PMN – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.20). On average, sell-side analysts predict that Promis Neurosciences will post -4.57 EPS for the current fiscal year.

Insider Activity

In related news, Director Patrick D. Kirwin acquired 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 22nd. The stock was acquired at an average price of $11.33 per share, with a total value of $45,320.00. Following the acquisition, the director directly owned 4,653 shares in the company, valued at $52,718.49. This represents a 612.56% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of Promis Neurosciences

Several hedge funds and other institutional investors have recently bought and sold shares of PMN. Citadel Advisors LLC raised its position in Promis Neurosciences by 168.1% during the third quarter. Citadel Advisors LLC now owns 170,079 shares of the company’s stock valued at $72,000 after acquiring an additional 106,650 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in Promis Neurosciences in the first quarter valued at approximately $135,000. ADAR1 Capital Management LLC purchased a new stake in Promis Neurosciences in the 1st quarter worth approximately $1,211,000. Armistice Capital LLC boosted its position in Promis Neurosciences by 39.1% in the 3rd quarter. Armistice Capital LLC now owns 2,974,518 shares of the company’s stock worth $1,264,000 after purchasing an additional 836,622 shares in the last quarter. Finally, Ally Bridge Group NY LLC grew its stake in shares of Promis Neurosciences by 367.1% during the 3rd quarter. Ally Bridge Group NY LLC now owns 6,233,497 shares of the company’s stock worth $2,649,000 after purchasing an additional 4,899,069 shares during the period. 50.13% of the stock is owned by institutional investors and hedge funds.

About Promis Neurosciences

(Get Free Report)

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.